Skip to main content
. Author manuscript; available in PMC: 2015 Jul 27.
Published in final edited form as: J Cancer Ther. 2012 Oct;3(5A):689–711. doi: 10.4236/jct.2012.325089

Figure 10.

Figure 10

Relative cytotoxic anti-neoplastic potency of covalent gemcitabine-(C4-amide)-[anti-HER2/neu] immunochemotherapeutic compared to anti-HER2/neu monoclonal immunoglobulin. Legends: (4) covalent gemcitabine-(C4-amide)-[anti-HER2/neu] immunochemotherapeutic; and (A) anti-HER2/neu monoclonal immunoglobulin. Chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) monolayer populations were incubated with gemcitabine-(C4-amide)-[anti-HER2/neu] and anti-HER2/neu monoclonal immunoglobulin formulated in triplicate at at gradient concentrations. Cytotoxic anti-neoplastic potency was measured using a MTT cell vitality assay relative to matched negative reference controls.